The last eight months have seen a resurgence in antivirals as researchers, scrambling for something that might treat Covid-19, repurposed approved HIV drugs and racked the libraries of small molecules on pharma and biotech’s shelves for any that could inhibit the novel virus. But yesterday, J&J took an antiviral it had been testing for 7 years and formally put it back on the shelf.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,